GlaxoSmithKline Pharmaceuticals Limited
1,010words
0turns
0analyst exchanges
0executives
Key numbers — 16 extracted
rs,
G Block Dalal Street Bandra-Kurla Complex, Bandra (East) Mumbai - 400001 Mumbai - 400051 Dear Sirs, Subject: Presentation of Analyst / Institutional Investor Meetings Pursuant to Regulation 30 read
124%
ult immunization as a category through Shingrix 5 Strong start in Oncology 38k Rxs for Q2 FY26 (124% YOY growth) ~400K ~5Mn Unique HCPs reached (F2F + Digital) Touchpoints (F2F + Digital) Source:
20%
h dMMR/MSI-H EC Maintenance monotherapy for patients with advanced or recurrent OC Unmet Need 20% of all Endometrial Cancers which are advanced or recurrent 2 ~80% of all Ovarian Cancer are Stag
80%
d or recurrent OC Unmet Need 20% of all Endometrial Cancers which are advanced or recurrent 2 ~80% of all Ovarian Cancer are Stage III/IV 3 EC: Endometrial Cancer, OC: Ovarian Cancer, dMMR: Mismat
₹974
n Experience - PMC 05 November 2025 5 Financial Highlights : Q2 FY 25-26 (Standalone) Revenue ₹974cr Growth -2.6% EBITDA ₹335cr Margin: 34.4% (+250 bps) Growth +4.9% PAT (before exceptional)
2.6%
MC 05 November 2025 5 Financial Highlights : Q2 FY 25-26 (Standalone) Revenue ₹974cr Growth -2.6% EBITDA ₹335cr Margin: 34.4% (+250 bps) Growth +4.9% PAT (before exceptional) ₹253cr Margin:
₹335
r 2025 5 Financial Highlights : Q2 FY 25-26 (Standalone) Revenue ₹974cr Growth -2.6% EBITDA ₹335cr Margin: 34.4% (+250 bps) Growth +4.9% PAT (before exceptional) ₹253cr Margin: 26.1% (+150 bp
34.4%
ncial Highlights : Q2 FY 25-26 (Standalone) Revenue ₹974cr Growth -2.6% EBITDA ₹335cr Margin: 34.4% (+250 bps) Growth +4.9% PAT (before exceptional) ₹253cr Margin: 26.1% (+150 bps) Growth +3.3%
250 bps
ghlights : Q2 FY 25-26 (Standalone) Revenue ₹974cr Growth -2.6% EBITDA ₹335cr Margin: 34.4% (+250 bps) Growth +4.9% PAT (before exceptional) ₹253cr Margin: 26.1% (+150 bps) Growth +3.3% EBITDA ma
4.9%
5-26 (Standalone) Revenue ₹974cr Growth -2.6% EBITDA ₹335cr Margin: 34.4% (+250 bps) Growth +4.9% PAT (before exceptional) ₹253cr Margin: 26.1% (+150 bps) Growth +3.3% EBITDA margin +250 bps (
₹253
cr Growth -2.6% EBITDA ₹335cr Margin: 34.4% (+250 bps) Growth +4.9% PAT (before exceptional) ₹253cr Margin: 26.1% (+150 bps) Growth +3.3% EBITDA margin +250 bps (YoY) PAT +150 bps (YoY) ▪ EBITD
26.1%
EBITDA ₹335cr Margin: 34.4% (+250 bps) Growth +4.9% PAT (before exceptional) ₹253cr Margin: 26.1% (+150 bps) Growth +3.3% EBITDA margin +250 bps (YoY) PAT +150 bps (YoY) ▪ EBITDA improved due
Advertisement